Clinical Trial

The Optimal Antibiotic Treatment Duration for Community-acquired Pneumonia in Adults Diagnosed in General Practice in Denmark (CAP-D)

Study acronym: CAP-D
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 17, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this randomised controlled trial is to identify the optimal treatment duration with phenoxymethylpenicillin for community-acquired pneumonia diagnosed in general practice. Eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute LRTI (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnea, sputum production, wheezing, chest discomfort or fever) in whom the GP finds it relevant to treat with antibiotics. Consenting patients who meet all the eligibility criteria will be randomised (1:1:1:1:1) to either three, four, five, six or seven days of treatment with phenoxymethylpenicillin 1.2 MIE four times daily.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-02-28; most recent amendment 2025-08-15.
Trial Details
NCT Number NCT06295120
Lead Sponsor Research Unit for General Practice in Aalborg
Conditions Community-acquired Pneumonia
Enrollment 600 participants
Start Date 2023-11-13
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-17